John P. Sharp
2021 - PhaseBio Pharmaceuticals
In 2021, John P. Sharp earned a total compensation of $780.8K as Chief Financial Officer at PhaseBio Pharmaceuticals, a 8% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $157,553 |
|---|---|
| Option Awards | $207,414 |
| Salary | $402,350 |
| Other | $13,439 |
| Total | $780,756 |
Sharp received $402.4K in salary, accounting for 52% of the total pay in 2021.
Sharp also received $157.6K in non-equity incentive plan, $207.4K in option awards and $13.4K in other compensation.
Rankings
In 2021, John P. Sharp's compensation ranked 9,558th out of 12,412 executives tracked by ExecPay. In other words, Sharp earned more than 23.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,558 out of 12,412 | 23rd |
Division Manufacturing | 4,236 out of 5,498 | 23rd |
Major group Chemicals And Allied Products | 1,878 out of 2,374 | 21st |
Industry group Drugs | 1,666 out of 2,095 | 21st |
Industry Pharmaceutical Preparations | 1,240 out of 1,542 | 20th |
Source: SEC filing on April 22, 2022.
Sharp's colleagues
We found two more compensation records of executives who worked with John P. Sharp at PhaseBio Pharmaceuticals in 2021.